ProCE Banner Activity

Hereditary Angioedema: Accounting for Unpredictability When Developing a Management Plan

Clinical Thought

In this commentary, Marc Riedl, MD, MS, discusses the important elements to consider when devising an effective management plan for patients with hereditary angioedema (HAE).

Released: October 31, 2022

Expiration: October 30, 2023

No longer available for credit.



Marc Riedl

Marc Riedl, MD, MS

Clinical Director
US HAEA Angioedema Center
University of California, San Diego
La Jolla, California


This activity is supported by educational grants from

BioCryst Pharmaceuticals, Inc.

Takeda Pharmaceuticals U.S.A., Inc.



ProCE Banner

Faculty Disclosure

Marc Riedl, MD, MS: researcher: Biocryst, CSL Behring, Ionis, Klavista, Pharvaris, Takeda; consultant/advisor/speaker: Astria, Biocryst, Biomarin, CSL Behring, Cycle Pharma, Ipsen, Klavista, Ono Pharma, Pfizer, Pharming, Pharvaris, RegenexBio, Spark, Takeda.

Additional Information

Program Medium

This program has been made available online.